Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Oxurion NV
  6. Nieuws
  7. Andere talen
    OXUR   BE0003846632

OXURION NV

(OXUR)
Real-time koersen. Real Time Euronext Bruxelles - 19/10 17:35:24
2.32 EUR   -1.28%
14/10BEURSAGENDA : Belgische bedrijven
AM
13/10BEURSAGENDA : Belgische bedrijven
AM
13/10Galapagos houdt Bel20 in het groen
AM
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Nieuws in andere talen op OXURION NV
13/10OXURION : Doses First Patient in Diabetic Macular Edema Drug Trial
13/10OXURION : Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the tr..
13/10Oxurion NV Announces First Patient Dosed in Its Phase 2 Study Evaluating THR-687 for th..
11/10OXURION : Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Spe..
11/10OXURION : Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Sp..
11/10OXURION : Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Sp..
05/10OXURION : to Present at the Lytham Partners Fall 2021 Investor Conference
30/09OXURION : Diabetic Macular Edema Drug Shows Favorable Safety Profile; Stock Jumps 19%
30/09OXURION : Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for T..
30/09OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for ..
09/09Oxurion Nv Reports Earnings Results for the Half Year Ended June 30, 2021
09/09OXURION : Business & Financial Update – H1 2021
17/08Oxurion NV Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 f..
16/08OXURION : Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD prof..
16/08Oxurion NV Announces Highlights Desirable PK/PD profiles of THR-687 and THR-149
05/08OXURION : to Participate in Upcoming Investor Meetings
10/06OXURION Confirms Institutional Review Board Approval and Submission of the Investigatio..
08/06OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for..
17/05Oxurion NV Announces Management Changes
17/05Oxurion Nv Announces Executive Changes
07/04OXURION : Publication in 'Progress in Retinal and Eye Research' highlights the potential o..
06/04Oxurion NV announced that it expects to receive Ä30 million in funding from Negma Group..
18/03Oxurion NV Business and Financial Update, FY 2020
17/03Oxurion Nv Reports Earnings Results for the Full Year Ended December 31, 2020
17/03Oxurion NV Announces Advancing Clinical Development of Next Generation Diabetic Macular..
20/01Oxurion Nv Appoints Prof Alan Stitt as Chief Scientific Officer
2020OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
2020OXURION : Confirms New Patents for THR-687 Issued by European and US Patent Offices
2020OXURION : Confirms New Patents for THR-687 Issued by European and US Patent Offices
2020OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
2020OXURION : ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid..
2020Oxurion NV Business Update, Q3 2020
2020OXURION : Business Update – Q3 2020
2020OXURION : Business Update – Q3 2020
2020Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
2020OXURION : appoints Tom Graney, CFA as Chief Financial Officer
2020OXURION : appoints Tom Graney, CFA as Chief Financial Officer
2020Oxurion NV Announces Executive Changes
2020Invitation OXURION R&D Investor Day, Virtual 15 October 2020 at 5.30pm CET/ 11.30am ET
2020OXURION : Invitation OXURION R&D Investor Day – Virtual 15 October 2020 at 5.30pm CE..
2020OXURION : Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm ..
2020SAVE THE DATE : Oxurion to host Virtual R&D Investor Day on 15 October 2020
2020SAVE THE DATE : Oxurion to host Virtual R&D Investor Day on 15 October 2020
2020Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting..
2020OXURION : to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oc..
2020OXURION : to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oc..
2020OXURION NV(ENXTBR : OXUR) dropped from S&P Global BMI Index
2020OXURION : Business Update, H1 2020
2020OXURION : Business Update - H1 2020
2020OXURION : Business Update - H1 2020
2020Oxurion Nv Reports Earnings Results for the Second Quarter Ended June 30, 2020
2020Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
2020OXURION : Business Update and First Half 2020 Financial Results to be announced on 17 Sept..
2020OXURION : to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
2020OXURION : to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
2020OXURION : Business Update and First Half 2020 Financial Results to be announced on 17 Sept..
2020OXURION : Business Update and First Half 2020 Financial Results to be announced on 17 Sept..
2020BICYCLE THERAPEUTICS : Announces First Patient Dosed in Oxurion's Phase II Trial Using a N..
2020Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatmen..
2020Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatmen..
2020Oxurion Nv Appoints Grace Chang as Chief Medical Officer Effective August 1, 2020
2020Oxurion NV Provides COVID-19 Statement
2020OXURION : Investigational Drug Vericiguat Significantly Reduced the Risk of the Oxurion NV..
2020OXURION : COVID-19 Statement
2020Oxurion Enters into Licensing Agreement with Inceptua
2020Oxurion Nv Reports Earnings Results for the Full Year Ended December 31, 2019
2020Oxurion NV - Expert Presentation of Positive Topline Data from a Phase 1 Study evaluati..
2020Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patien..
2020Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patien..
2020OXURION NV : flambe sur des données précoces mais positives sur THR-687
2020Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for trea..
2019Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel,..
2019Thrombogenics Nv Reports Earnings Results for the Half Year Ended June 30, 2019
2019Oxurion NV Announces Positive Topline Phase 1 Results with THR-149
2019Oxurion NV Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687
1  2  3  4  5Volgende
Komende gebeurtenissen in de sector